Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$7.92 and traded as high as C$8.88. Cipher Pharmaceuticals shares last traded at C$8.82, with a volume of 6,227 shares.
Analysts Set New Price Targets
Separately, Citigroup lifted their price target on shares of Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the company a “buy” rating in a report on Wednesday, February 14th.
Get Our Latest Analysis on Cipher Pharmaceuticals
Cipher Pharmaceuticals Stock Performance
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last issued its quarterly earnings results on Thursday, March 14th. The company reported C$0.41 EPS for the quarter, beating analysts’ consensus estimates of C$0.15 by C$0.26. The business had revenue of C$6.70 million for the quarter, compared to analysts’ expectations of C$7.31 million. Cipher Pharmaceuticals had a net margin of 96.32% and a return on equity of 28.19%. On average, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 0.6040609 earnings per share for the current fiscal year.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- Consumer Discretionary Stocks Explained
- United Airlines Soars on Earnings Beat
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.